Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$800M |
| 2 |
NVIDIA
NVDA
|
+$304M |
| 3 |
Broadcom
AVGO
|
+$261M |
| 4 |
Linde
LIN
|
+$237M |
| 5 |
JPMorgan Chase
JPM
|
+$208M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Costco
COST
|
+$656M |
| 2 |
Netflix
NFLX
|
+$632M |
| 3 |
Tesla
TSLA
|
+$474M |
| 4 |
Procter & Gamble
PG
|
+$428M |
| 5 |
Micron Technology
MU
|
+$332M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.04% |
| 2 | Healthcare | 15.34% |
| 3 | Industrials | 11.14% |
| 4 | Consumer Discretionary | 10.86% |
| 5 | Financials | 10.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1926
Empire State Realty Trust
ESRT
$815M
| $1.89M | ﹤0.01% |
363,700
+130,100
| +56% | +$781K |
2024 Q1
8 quarters
|
|
1927
Unisys
UIS
$161M
| $1.89M | ﹤0.01% |
912,900
-410,333
| -31% | -$1.03M |
2022 Q4
13 quarters
|
|
1928
Eastman Chemical
EMN
$7.15B
| $1.89M | ﹤0.01% |
24,740
-232,700
| -90% | -$16.8M |
2024 Q3
6 quarters
|
|
1929
Docebo
DCBO
$637M
| $1.89M | ﹤0.01% |
108,031
-7,000
| -6% | -$134K |
2020 Q4
21 quarters
|
|
1930
Yatsen Holding
YSG
$244M
| $1.89M | ﹤0.01% |
612,593
+94,286
| +18% | +$379K |
2021 Q3
18 quarters
|
|
1931
NeoGenomics
NEO
$2.05B
| $1.89M | ﹤0.01% |
+254,172
| New | +$2.67M |
2026 Q1
0 quarters
|
|
1932
Aclaris Therapeutics
ACRS
$537M
| $1.88M | ﹤0.01% |
502,631
-622,700
| -55% | -$2.1M |
2018 Q4
29 quarters
|
|
1933
Trio-Tech International Common Stock
TRT
$57.5M
| $1.88M | ﹤0.01% |
325,526
+170
| +0.1% | +$997 |
2013 Q2
51 quarters
|
|
1934
Celanese
CE
$4.92B
| $1.87M | ﹤0.01% |
28,500
-423,600
| -94% | -$22.1M |
2025 Q4
1 quarter
|
|
1935
Murphy Oil
MUR
$5.69B
| $1.87M | ﹤0.01% |
45,437
-6,800
| -13% | -$230K |
2024 Q3
6 quarters
|
|
1936
Zura Bio
ZURA
$390M
| $1.86M | ﹤0.01% |
313,300
+10,200
| +3% | +$61.6K |
2023 Q4
9 quarters
|
|
1937
DELISTED
Janus Henderson
JHG
| $1.86M | ﹤0.01% |
36,200
-46,300
| -56% | -$2.29M |
2025 Q4
1 quarter
|
|
1938
Knowles
KN
$3.13B
| $1.86M | ﹤0.01% |
72,400
-24,974
| -26% | -$632K |
2017 Q1
36 quarters
|
|
1939
CION Investment
CION
$338M
| $1.86M | ﹤0.01% |
271,800
+11,000
| +4% | +$92.4K |
2022 Q1
16 quarters
|
|
1940
ReposiTrak
TRAK
$141M
| $1.85M | ﹤0.01% |
243,963
+55,700
| +30% | +$535K |
2019 Q2
27 quarters
|
|
1941
Airgain
AIRG
$54.1M
| $1.85M | ﹤0.01% |
336,336
+14,700
| +5% | +$66.9K |
2019 Q1
28 quarters
|
|
1942
Invesco S&P 500 Quality ETF
SPHQ
$19.1B
| $1.85M | ﹤0.01% |
+24,600
| New | +$1.91M |
2026 Q1
0 quarters
|
|
1943
Taysha Gene Therapies
TSHA
$1.37B
| $1.85M | ﹤0.01% |
413,203
+242,103
| +141% | +$1.13M |
2025 Q4
1 quarter
|
|
1944
Sypris Solutions
SYPR
$44.4M
| $1.84M | ﹤0.01% |
646,656
-32,565
| -5% | -$104K |
2013 Q2
51 quarters
|
|
1945
Walker & Dunlop
WD
$1.11B
| $1.84M | ﹤0.01% |
41,500
-54,300
| -57% | -$3.06M |
2025 Q1
4 quarters
|
|
1946
Flexible Solutions
FSI
$77.4M
| $1.84M | ﹤0.01% |
340,945
+7,751
| +2% | +$44.6K |
2015 Q2
43 quarters
|
|
1947
Canton Strategic Holdings
CNTN
$170M
| $1.84M | ﹤0.01% |
+562,000
| New | +$2.22M |
2026 Q1
0 quarters
|
|
1948
Valhi
VHI
$404M
| $1.84M | ﹤0.01% |
128,417
-8,500
| -6% | -$120K |
2014 Q2
47 quarters
|
|
1949
Microchip Technology
MCHP
$40.2B
| $1.83M | ﹤0.01% |
28,356
-1,188,100
| -98% | -$85.5M |
2025 Q3
2 quarters
|
|
1950
BRC Group Holdings
RILY
$211M
| $1.83M | ﹤0.01% |
+250,218
| New | +$1.87M |
2026 Q1
0 quarters
|
|
Similar funds
Renaissance Technologies's Q1 2026 Portfolio in Review
As of Q1 2026, Renaissance Technologies held 3,809 positions worth $63.9B, down 0.82% from $64.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q1 2026 filing shows 624 new, 1,320 increased, 1,262 reduced and 596 closed positions. Its largest new stake was Apple: 3,075,638 shares worth $781M. The largest sale was Costco, an estimated $656M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Healthcare and Industrials.
- Renaissance Technologies's largest Q1 2026 buy was Apple: 3,075,638 shares worth $781M.
- Renaissance Technologies added most to NVIDIA in Q1 2026, an estimated $304M increase.
- Renaissance Technologies's biggest Q1 2026 reduction was Costco, cutting an estimated $656M.
- Renaissance Technologies fully exited Procter & Gamble in Q1 2026, selling an estimated $428M.
- Renaissance Technologies's ten largest holdings make up 11% of its $63.9B portfolio in Q1 2026.
- Renaissance Technologies opened 624 new positions and closed 596 in Q1 2026.
- Renaissance Technologies's portfolio value fell 0.82% quarter-over-quarter to $63.9B.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.